Skip to main content
. Author manuscript; available in PMC: 2014 Jun 21.
Published in final edited form as: Clin Cancer Res. 2012 Apr 17;18(12):3440–3451. doi: 10.1158/1078-0432.CCR-11-2852

Figure 2.

Figure 2

Anterior whole body, planar In-111 pentreotide gamma camera images of a representative patient before (A) and after (B) Ad treatment (highest Ad dose cohort) show diffuse peritoneal activity following therapy (arrows) as well as normal distribution in liver, spleen, bowel, and urine. The image in (B) was at 1 day after the last Ad5.SSTR/TK.RGD dose (of 3 doses given over 3 days). Therefore, the single imaging time point post Ad5.SSTR/TK.RGD therapy was at 24, 48, and 72 hours after the three respective Ad5.SSTR/TK.RGD doses. This time point is coincided with the highest levels of TK expression according to our ancillary studies evaluating TK expression in peritoneal aspirates.

HHS Vulnerability Disclosure